Contrasting effects of exercise, AICAR, and increased fatty acid supply on in vivo and skeletal muscle glucose metabolism.
The increased energy required for acute moderate exercise by skeletal muscle (SkM) is derived equally from enhanced fatty acid (FA) oxidation and glucose oxidation. Availability of FA also influences contracting SkM metabolic responses. Whole body glucose turnover and SkM glucose metabolic responses were determined in paired dog studies during 1) a 30-min moderate exercise (maximal oxygen consumption of approximately 60%) test vs. a 60-min low-dose 5-aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside (AICAR) infusion, 2) a 150-min AICAR infusion vs. modest elevation of FA induced by a 150-min combined intralipid-heparin (IL/hep) infusion, and 3) an acute exercise test performed with vs. without IL/hep. The exercise responses differed from those observed with AICAR: plasma FA and glycerol rose sharply with exercise, whereas FA fell and glycerol was unchanged with AICAR; glucose turnover and glycolytic flux doubled with exercise but rose only by 50% with AICAR; SkM glucose-6-phosphate rose and glycogen content decreased with exercise, whereas no changes occurred with AICAR. The metabolic responses to AICAR vs. IL/hep differed: glycolytic flux was stimulated by AICAR but suppressed by IL/hep, and no changes in glucose turnover occurred with IL/hep. Glucose turnover responses to exercise were similar in the IL/hep and non-IL/hep, but SkM lactate and glycogen concentrations rose with IL/hep vs. that shown with exercise alone. In conclusion, the metabolic responses to acute exercise are not mimicked by a single dose of AICAR or altered by short-term enhancement of fatty acid supply.
Rantzau
C
C
Dept. of Endocrinology and Diabetes, 4th Floor Daly Wing, St Vincent's Health, 35 Victoria St., Fitzroy Victoria 3065, Australia.
Christopher
M
M
Alford
F P
FP
D000620:Aminoimidazole Carboxamide / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D004285:Dogs; D004734:Energy Metabolism / Q000187:drug effects; D005217:Fat Emulsions, Intravenous / Q000008:administration & dosage / Q000378:metabolism*; D005227:Fatty Acids / Q000097:blood / Q000378:metabolism*; D005947:Glucose / Q000378:metabolism*; D019298:Glucose-6-Phosphate / Q000378:metabolism; D005990:Glycerol / Q000097:blood; D006003:Glycogen / Q000378:metabolism; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007263:Infusions, Parenteral; D019344:Lactic Acid / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D008297:Male; D009119:Muscle Contraction; D018482:Muscle, Skeletal / Q000187:drug effects / Q000378:metabolism*; D010084:Oxidation-Reduction; D010101:Oxygen Consumption; D005082:Physical Exertion / Q000502:physiology*; D012265:Ribonucleotides / Q000008:administration & dosage*; D013997:Time Factors
D001786:Blood Glucose; D005217:Fat Emulsions, Intravenous; D005227:Fatty Acids; D007004:Hypoglycemic Agents; D012265:Ribonucleotides; D019344:Lactic Acid; D000620:Aminoimidazole Carboxamide; D019298:Glucose-6-Phosphate; D006003:Glycogen; C031143:AICA ribonucleotide; D005947:Glucose; D005990:Glycerol